You are viewing the site in preview mode

Skip to main content


  • Poster presentation
  • Open Access

Intravenous injection of a modified vaccinia ankara virus induces intratumoral CD8+ lymphocyte infiltration favoring tumor control in an orthotopic tumor model upon combinatorial treatment with a TLR9 agonist

  • 1,
  • 2,
  • 2,
  • 3,
  • 1,
  • 1,
  • 1,
  • 4 and
  • 2
Journal for ImmunoTherapy of Cancer20142 (Suppl 3) :P57

  • Published:


  • Vaccinia
  • Renal Carcinoma
  • Immune Checkpoint
  • Orthotopic Tumor
  • Modify Vaccinia Ankara Virus


There are many critical steps for the clinical efficacy of antigen-specific T cell-based immunotherapies among which traffic to and access to tumor beds of effector T cells, are the most limiting [1]. Preclinical research most often uses ectopic mouse tumor models for the readout fastness and easiness provided by such models. However, those models may not be the optimal way to address the issue of targeting effector T cells to a deep organ born tumor.


We set up an orthotopic preclinical model in which renal carcinoma cells (RenCa) expressing the human mucin 1 tumor-associated xeno-antigen are injected into the sub-capsular space of kidney in BALB/c mice. We then evaluated the impact of the route of injection on the therapeutic efficacy of a Modified Vaccinia virus Ankara expressing the human mucin 1 xeno-antigen (MVA-MUC1).


We show that intravenous administration of MVA-MUC1 is therapeutically superior to subcutaneous injection. Therapeutic efficacy of MVA-MUC1 can be further enhanced by intravenous administration of a TLR9 ligand (ODN1826). Substantial and necessary infiltration of tumor-bearing kidneys by CD8+ lymphocytes is associated with therapeutic protection. We observe that infiltration of CD8+ lymphocytes is not limited to tumor-bearing kidneys and is also detected in naive kidneys, liver and lungs. Kidney infiltrating lymphocytes are characterized by an effector memory phenotype and express PD-1 and Tim3 immune checkpoints molecules. Biodistribution experiments indicate that MVA encoded antigens quickly reach deep organs and in particular APC from the spleen upon i.v. injection of MVA in comparison to s.c. injection, resulting in a faster generation of MUC1 specific CD8+ T cells. Unexpectedly, addition of ODN1826 to MVA-MUC1 immunization does not result in an increase in the frequency of MUC1 specific T cells detected in the spleen. Instead, ODN1826 was associated with a more pronounced modification of the tumor microenvironment towards a TH1 type inflammatory response and a recruitment of activated lymphocytes.


Intravenous injection of MVA-MUC1 is associated with therapeutic efficacy and deep organ infiltration by MUC1-specific CD8+ T cells in an orthotopic model of renal carcinoma. This therapeutic efficacy can be further increased through the use of ODN1826. This study supports the clinical evaluation of MVA-based immunotherapies via the intravenous route.

Authors’ Affiliations

Transgene, France
Transgene, Illkirch-Graffenstaden Cedex, France
Transgene, Gambia
CNRS-Université de Strasbourg, Illkirch Graffenstaden cedex, France


  1. Chen DS, Mellman I: Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013, 39: 1-10. 10.1016/j.immuni.2013.07.012.View ArticlePubMedGoogle Scholar


© Fend et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.